pI: 8.8423 |
Length (AA): 407 |
MW (Da): 45450 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Ortholog group members (OG5_131934)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT5G21326 | CBL-interacting serine/threonine-protein kinase 26 |
Arabidopsis thaliana | AT1G01140 | CBL-interacting serine/threonine-protein kinase 9 |
Arabidopsis thaliana | AT1G30270 | CBL-interacting serine/threonine-protein kinase 23 |
Arabidopsis thaliana | AT2G26980 | CBL-interacting serine/threonine-protein kinase 3 |
Leishmania braziliensis | LbrM.07.0960 | serine/threonine kinase, putative,protein kinase, putative |
Leishmania donovani | LdBPK_071030.1 | serine/threonine kinase, putative |
Leishmania infantum | LinJ.07.1030 | serine/threonine kinase, putative,protein kinase, putative |
Leishmania major | LmjF.07.0900 | serine/threonine kinase, putative,protein kinase, putative |
Leishmania mexicana | LmxM.07.0900 | serine/threonine kinase, putative,protein kinase, putative |
Oryza sativa | 4332665 | Os03g0319400 |
Oryza sativa | 4342410 | Os07g0150700 |
Oryza sativa | 4349698 | Os11g0134300 |
Oryza sativa | 4331474 | Os03g0126800 |
Oryza sativa | 4344342 | Os07g0687000 |
Oryza sativa | 4351419 | Os12g0132200 |
Trypanosoma brucei gambiense | Tbg972.8.490 | serine/threonine kinase, putative |
Trypanosoma brucei | Tb927.8.870 | CAMK/CAMKL family protein kinase, putative |
Trypanosoma congolense | TcIL3000_0_36270 | serine/threonine kinase, putative |
Trypanosoma cruzi | TcCLB.510861.140 | CAMK/CAMKL family protein kinase, putative |
Trypanosoma cruzi | TcCLB.509607.70 | CAMK/CAMKL family protein kinase, putative |
Trichomonas vaginalis | TVAG_315190 | CAMK family protein kinase |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.8.870 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.8.870 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.8.870 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.8.870 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Schizosaccharomyces pombe 972h- | Casein kinase II subunit alpha | 332 aa | 25.1% | 299 aa | Compounds | References |
Homo sapiens | Cyclin-dependent kinase 1/cyclin B1 | 297 aa | 23.5% | 289 aa | Compounds | References |
Rattus norvegicus | Jak1 protein | 210 aa | 28.1% | 196 aa | Compounds | References |
Rattus norvegicus | Mitogen-activated protein kinase 1 | 358 aa | 26.3% | 342 aa | Compounds | References |
Rattus norvegicus | MAP kinase p38 alpha | 360 aa | 26.0% | 296 aa | Compounds | References |
Rattus norvegicus | Serine/threonine-protein kinase pim-3 | 326 aa | 28.0% | 261 aa | Compounds | References |
Rattus norvegicus | Cell division protein kinase 5 | 292 aa | 26.0% | 292 aa | Compounds | References |
Plasmodium falciparum (isolate 3D7) | Cell division control protein 2 homolog | 288 aa | 28.1% | 288 aa | Compounds | References |